康龙化成 (300759)

Pharmaron Beijing Co., Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexContract Research Organization (CXO)MSCI Mid Cap IndexCSI 200 IndexInnovative DrugsMedical ServicesSTAR and ChiNext 50 IndexContains H-SharesGuozheng Growth IndexFund Heavy PositionsLarge Cap GrowthEmerging Markets IndexPrivate Enterprises 100 IndexOverseas BusinessR&DHigh-Performing StocksShareholder ReductionNon-Cyclical StocksChiNext Large CapChiNext 50 IndexChiNext IndexChiNext HealthcareSZSE 100 IndexSZSE 300 IndexSZSE Growth IndexPharma & BiotechTechnology Leaders IndexSHS Technology Leaders IndexConsumer Services IndexSZSE Medicine Equal Weight IndexSZSE 100 Equal Weight IndexMid-cap High Beta IndexZhongchuang Equal Weight IndexCSI Emerging Industries IndexJuchao Large-cap IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexChiNext Equal Weight IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexZhongchuang Growth IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexCSWD Life Sciences IndexShanghai-Hong Kong-Shenzhen 300 IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCS Beijing-Tianjin-Hebei IndexBiomedicine IndexCSI Medical IndexCS Precision Medicine IndexOrient Securities Value IndexChiNext Value IndexCSI 300 Non-cyclical IndexCNI Emerging Industries IndexCS High-end Manufacturing IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexSTAR Market & ChiNext 50 IndexSZSE Technology IndexSZSE Leaders IndexCSI 300 ESG Leading IndexSZSE 100 Return IndexSHS Innovative Drugs IndexSZSE High Beta IndexSustainable Development IndexCSI 300 Growth IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexESG 100 IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexChiNext Basic IndexSZSE Private Enterprises IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexZhongguancun 60 IndexPharmaceutical Sub-sector IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSmart Select 300 ESG Leading IndexSZSE 300 Equal Weight IndexChiNext Low Volatility IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexCSI 300 Pharmaceutical IndexCSI 700 IndexAH Economic Blue-chip IndexMid-small Cap IndexPharmaceutical 50 IndexZhongchuang High Beta IndexScientific Research IndexPharmaceutical 50 Strategy IndexCSI Life Sciences IndexSZSE 200 Return IndexSZSE 200 IndexChiNext High Beta IndexCS Innovative Drugs IndexChiNext Growth IndexESG 300 IndexCR New Momentum IndexChina Economic Index GDPChiNext Return IndexJuchao Mid-cap IndexChiNext Emerging IndexChiNext Growth IndexStrategic Emerging Industries 100 Index

K-Line Chart

No K-line data available

Company NamePharmaron (Beijing) New Drug Technology Co., Ltd.
Listing Date2019-01-28
Issue Price7.66RMB
Registered Capital177819.552510k RMB
Legal RepresentativeBoliang Lou
Registered Address8th Floor, Building 1, No. 6 Taihe Road, Beijing Economic-Technological Development Area, Beijing
IndustryMedical Services
Main BusinessThe company provides global pharmaceutical enterprises, biotechnology R&D companies, and research institutions with a full-process integrated CRMO (Contract Research, Development and Manufacturing Organization) solution spanning the two stages of drug discovery and drug development. It is committed to helping partners succeed in new drug discovery, development, and commercialization.
Company ProfilePharmaron New Drug Technology Co., Ltd., founded in 2004, is an internationally leading life science R&D service enterprise. The company's mission is 'To contribute Pharmaron's wisdom to human health by providing the highest level of R&D services to help our partners successfully develop new drugs.' After more than a decade of rapid development, Pharmaron has built a comprehensive, integrated drug R&D platform covering various fields including synthetic and medicinal chemistry, biology, drug metabolism and pharmacokinetics, pharmacology, drug safety evaluation, radiolabeled metabolism, process development, GMP manufacturing, and formulation development services. It provides integrated services ranging from hit compound exploration and target validation, lead compound optimization, preclinical candidate screening, new drug clinical development, to new drug application submission. Pharmaron has operating entities in China, the United States, and the United Kingdom, with over 7,000 employees. Its first-class talent team and high-quality R&D services have gained widespread recognition in the industry, maintaining long-term and stable cooperative relationships with various pharmaceutical companies/institutions in North America, Europe, Japan, and China.

Stock Details

1. Key Indicators

  • Total Shares(W): 177819.55
  • Circulating A-Shares(W): 141938.46
  • Earnings Per Share(RMB): 0.6477
  • Net Assets Per Share(RMB): 8.2179
  • Operating Revenue(W RMB): 1008562.32
  • Total Profit(W RMB): 132893.38
  • Net Profit Attributable to Parent(W RMB): 114091.22
  • Net Profit Growth Rate(%): -19.76
  • Weighted Return on Equity(%): 8.0500
  • Operating Cash Flow Per Share(RMB): 1.3700
  • Undistributed Profit Per Share(RMB): 4.0665
  • Capital Reserve Per Share(RMB): 2.7732

2. Main Business

The main business covers:

  • Laboratory Services
  • CMC (Small Molecule CDMO) Services
  • Clinical Research Services
  • Macromolecule and Cell & Gene Therapy Services

3. Company Basic Information

  • Company Name: Pharmaron Beijing Co., Ltd.
  • Listing Date: 2019-01-28
  • Industry: Research and Experimental Development
  • Address: No. 6 Taihe Road, Beijing Economic-Technological Development Area, Beijing, China
  • Website: www.pharmaron.com
  • Company Profile: On July 21, 2016, Pharmaron Limited held a board meeting and agreed to change the company into a joint stock company. All shareholders of Pharmaron Limited signed the "Sponsor Agreement" as sponsors. Based on the audited net assets of Pharmaron Limited as of February 29, 2016, amounting to RMB 938,500,686.29, the company was converted into 500,000,000 shares to establish the joint stock company. The portion of net assets exceeding the share capital was recorded as the issuer's capital reserve. On August 4, 2016, the Management Committee of Beijing Economic-Technological Development Area approved the change of Pharmaron (Beijing) New Drug Technology Co., Ltd. into a foreign-invested joint stock company with the approval document (Jing Ji Guan Xiang Shen Zi [2016] No. 175). On August 8, 2016, the Beijing Municipal Government reissued the "Foreign Investment Enterprise Approval Certificate" (Shang Wai Zi Jing Zi [2004] No. 17150) to the issuer. On August 9, 2016, ShineWing verified the company's registered capital and issued the "Capital Verification Report" (XYZH/2016BJA30207), confirming that the shareholders' contributions were in place. On October 25, 2016, the issuer held its inaugural meeting. On October 27, 2016, the Beijing Administration for Industry and Commerce issued the "Business License" (Unified Social Credit Code: 9111030276350109XG) to the issuer.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership) General Legal Person 22348.83 15.75
2 PHARMARON HOLDINGS LIMITED General Legal Person 18049.65 12.72
3 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 7235.62 5.10
4 Hong Kong Securities Clearing Company Ltd. Northbound Funds 5315.60 3.75
5 Ningbo Longtaikang Investment Management Co., Ltd. General Legal Person 4013.50 2.83
6 Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) General Legal Person 2849.85 2.01
7 Huabao China Securities Medical Care ETF Fund 2506.59 1.77
8 Beihai Duotai Venture Capital Co., Ltd. General Legal Person 2195.70 1.55
9 E Fund ChiNext ETF Fund 2015.01 1.42
10 China Merchants China Securities Bio-pharmaceutical Index Fund (LOF) Class A Fund 1347.02 0.95

5. Concept Sectors

  • H-Share
  • Artificial Intelligence
  • CXO Concept
  • Innovative Drugs
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Heavily Held by Funds
  • Shareholder Reduction
  • MSCI Mid Cap
  • Overseas Business
  • Non-Cyclical Stocks
  • Zhongchuang 100
  • ChiNext Index
  • SZSE 300
  • Private Enterprise 100
  • SZSE Growth
  • CSI 300
  • ChiNext 50
  • ChiNext 300
  • CSI 200
  • 300 Non-Cyclical
  • ChiNext Large Cap
  • ChiNext Healthcare
  • STAR 50
  • 300 ESG

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information